/

PRN.TO

PROFOUND MEDICAL CORPClosed

9.40−0.59 −5.91%CAD

Toronto · as of Oct 14, 15:59 ET · 15m delay

Open

10.02

Prev close

9.99

Day range

9.3510.07

52-week range

6.5212.40

Volume

7.40K0.50×

Mkt cap

343.48M

P/E ttm

—

Fwd P/E

-11.35

EPS ttm

-1.37

Div yield

0.00%

Earnings

Nov 5, 2026

From 52w high

−24.19%

Price Chart

Yahoo Finance · delayed

PRN.TOOct 14, 2026O 10.02H 10.07L 9.35C 9.40−0.59 (−5.91%)Vol 7.40K

SMA 509.16
SMA 2009.43

1Y change +17.50% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PRN.TO PROFOUND MEDICAL CORP · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +15.20%
1 month: +17.06%
3 months: −4.47%
6 months: +5.62%
Year to date: −12.72%
1 year: +16.34%

Valuation & ownership

Market cap: 343.48M
Enterprise value: 334.07M
P/E (ttm): —
Forward P/E: -11.35
PEG ratio: —
Price / book: 4.83
Price / sales (ttm): 18.00
EV / EBITDA: -9.58
EPS (ttm): -1.37
EPS (forward): -0.8282
Beta (5y monthly): 0.56
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 36.54M
Float: 35.50M
Short % of float: 1.05%
Short ratio (days): 28.45
Held by insiders: 4.09%
Held by institutions: 45.01%
Avg volume (3m): 14.73K
50-day average: 9.18
200-day average: 9.43
52-week change: +16.34%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 56.3
vs 50-day SMA: +2.63%
vs 200-day SMA: −0.31%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 5.65%
Realised vol (20d, ann.): 81.8%
From 52-week high: −24.19%
From 52-week low: +44.17%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 19.09M
Revenue growth (yoy): +12.30%
Earnings growth (yoy): —
Gross margin: 71.79%
Operating margin: -445.67%
Profit margin: -171.56%

DES

About PROFOUND MEDICAL CORP

Yahoo Finance profile

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.

Sector: Healthcare
Industry: Medical Devices
Employees: 162
Headquarters: Mississauga, ON, Canada
Website: profoundmedical.com
Officers: Dr. Arun Swarup Menawat MBA, Ph.D. Chairman of the Board & CEO
Dr. Mathieu Burtnyk Ph.D. Chief Technology Officer
Mr. Thomas Tamberrino MBA Chief Commercial Officer
Mr. Richard R. Fabian President

SEAS

Seasonality · PRN.TO

2018–2026 · monthly returns

Strongest month Dec +18.18%Weakest month Mar −15.43%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-5.2	1.2	-13.8	2.4	4.6	-1.0	10.1	-9.0	-11.7	12.7			−12.7%
2025	-14.1	6.6	-17.0	-15.6	4.0	12.3	-3.8	-20.9	10.4	22.9	8.6	18.6	−0.3%
2024	6.9	5.4	-8.7	-8.9	-3.7	17.1	25.0	-15.6	-12.9	-5.7	12.7	-5.6	−2.7%
2023	13.7	9.3	-30.4	24.7	6.0	2.5	-12.7	-18.8	13.1	-15.6	26.0	-23.3	−23.3%
2022	-11.6	7.6	-17.0	-16.4	23.7	-19.2	17.3	-18.4	-37.9	0.2	16.1	122.8	+1.5%
2021	27.3	-15.1	-11.0	-11.2	-5.5	-4.5	-9.5	1.9	-0.7	-9.8	-15.9	1.7	−45.6%
2020	52.0	-21.9	-22.6	38.8	-9.3	34.8	-7.4	-9.8	21.9	-3.1	14.5	0.8	+77.6%
2019	50.9	-2.4	-1.2	17.5	-8.5	-8.1	1.3	26.3	6.9	17.6	-18.9	43.2	+168.2%
2018								-10.0	-20.0	-15.3	3.3	-12.7	−45.0%

INSD

Insider Activity · PRN.TO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 16, 2026	Fabian (Richard Ringler)Senior Officer of Issuer	Acquisition in the public market at price 5.98 per share.	10K	$59.80K
Sep 10, 2026	Burtnyk (Mathieu)Senior Officer of Issuer	Exercise of rights at price 6.77 per share.	3K	$20.11K
Sep 10, 2026	Ellacott Brian RDirector of Issuer	Exercise of rights at price 6.77 per share.	739	$5.00K
Sep 10, 2026	Lortie (Murielle Cpa)Director of Issuer	Exercise of rights at price 6.77 per share.	739	$5.00K
Sep 10, 2026	Menawat (Arun Swarup Ph.D.)Director of Issuer	Exercise of rights at price 6.77 per share.	12.5K	$84.38K
Sep 10, 2026	Rosenthal (Arthur Lee)Director of Issuer	Exercise of rights at price 6.77 per share.	885	$5.99K
Sep 10, 2026	Sobczyk (Matthew Cpa)Senior Officer of Issuer	Exercise of rights at price 6.77 per share.	1.1K	$7.39K
Sep 7, 2026	Lavoie (Cynthia Ph.D.)Director of Issuer	Exercise of rights at price 6.81 per share.	1.7K	$11.36K
Aug 31, 2026	Fabian (Richard Ringler)Senior Officer of Issuer	—	0	—
Aug 16, 2026	Tamberrino (Thomas Michael)Senior Officer of Issuer	Acquisition in the public market at price 6.69 per share.	3.8K	$25.14K
Aug 13, 2026	Sobczyk (Matthew Cpa)Senior Officer of Issuer	—	0	—
Jun 28, 2026	Ellacott Brian RDirector of Issuer	Exercise of rights at price 6.43 per share.	1.8K	$11.33K
Jun 28, 2026	Lortie (Murielle Cpa)Director of Issuer	Exercise of rights at price 6.43 per share.	1.8K	$11.32K
Jun 28, 2026	Rosenthal (Arthur Lee)Director of Issuer	Exercise of rights at price 6.43 per share.	2.1K	$13.63K
Jun 23, 2026	Burtnyk (Mathieu)Senior Officer of Issuer	Exercise of rights at price 6.51 per share.	11.7K	$76.16K
Jun 23, 2026	Dewan (Rashed Osman)Senior Officer of Issuer	Exercise of rights at price 6.51 per share.	7.8K	$50.76K
Jun 23, 2026	Lavoie (Cynthia Ph.D.)Director of Issuer	Exercise of rights at price 6.74 per share.	4K	$27.20K
Jun 23, 2026	Menawat (Arun Swarup Ph.D.)Director of Issuer	Exercise of rights at price 6.51 per share.	74.6K	$485.57K
Jun 23, 2026	Tamberrino (Thomas Michael)Senior Officer of Issuer	Exercise of rights at price 6.51 per share.	10.6K	$68.89K
Mar 19, 2026	Menawat (Arun Swarup Ph.D.)Director of Issuer	Acquisition in the public market at price 5.10 per share.	20K	$101.92K

PRN.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PRN.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About PROFOUND MEDICAL CORP

Seasonality · PRN.TO

Insider Activity · PRN.TO

Congress Trades · PRN.TO

Investors Holding PRN.TO

Investors Holding PRN.TO

Insider Activity · PRN.TO

Seasonality · PRN.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About PROFOUND MEDICAL CORP

Earnings & Dividends

News

Congress Trades · PRN.TO